AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Roxadustat (evrenzo) by Quarter
Roxadustat (evrenzo) — Established RoW product sales ($M) ($M)
AstraZeneca Roxadustat (evrenzo): $0M in Q2 2026. That is the highest of the 22 quarters on record here.
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| roxadustat | 14 | | ( 81 ) | | ( 82 ) | | - | | - | | 14 | | ( 81 ) | | ( 82 ) | | - | | - | | - | | - | | - | | -”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up roxadustat (evrenzo)
Cite this data
StockData. (2026). AstraZeneca Roxadustat (evrenzo) ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-roxadustat-erow
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.